Ternary Therapeutics, a London-based biotechnology company, has raised €4.1 million (£3.6 million) in a seed funding round to advance its artificial intelligence-powered platform for drug discovery. The round was led by daphni, with participation from Pace Ventures, the i&i Biotech Fund, and the UK Innovation & Science Seed Fund (UKI2S), which is managed by Future Planet Capital. The funding will support the company’s efforts to scale its platform and accelerate the development of molecular glue therapeutics.
Ternary Therapeutics is focused on designing molecular glues, a class of drugs that enable protein-protein interactions to target diseases previously considered “undruggable.” By bringing proteins together, these therapies open up new possibilities for treating conditions that conventional drugs cannot address.
The company’s platform combines physics-informed artificial intelligence with rapid experimental validation, aiming to transform drug discovery from a largely trial-and-error process into a repeatable engineering system. This approach aims to improve efficiency and predictability in identifying viable therapeutic candidates.
As part of its next phase of growth, Ternary Therapeutics has appointed Dr. Ian Taylor to its board of directors. Dr. Taylor brings extensive experience in targeted protein degradation research and previously served as Chief Scientific Officer and President of R&D at Arvinas.
The newly raised capital will also be used to expand the company’s capabilities, grow its team, and advance its pipeline of programs toward preclinical development, particularly in inflammatory and neuroinflammatory diseases.
